Is the Search for a Cure for Alzheimer’s Disease Hopeless?

Is the Search for a Cure for Alzheimer’s Disease Hopeless?

It is likely that in one’s lifetime a friend or family member will be diagnosed with Alzheimer’s disease. As of 2018, approximately 50 million people worldwide are living with dementia and this number is expected to triple to 152 million by 2050.[1]

Despite the increasing prevalence of the disease, no new drugs have been approved for the treatment of Alzheimer’s since 2003.[2] An article recently published on PharmaTimes proclaims, “The search for a cure for Alzheimer’s is far from over.”[3]

Continue reading “Is the Search for a Cure for Alzheimer’s Disease Hopeless?”

Ocrelizumab (Ocrevus®): Now also approved in the EU

Ocrelizumab (Ocrevus®): Now also approved in the EU

Ocrelizumab has now also been approved in the EU for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical and imaging features.[1] This European approval in January 2018, followed two previous approvals in 2017, granted to Genentech, the developers,  initially in the US (March) [2] and later in Canada (August)[3] for the same indication. Continue reading “Ocrelizumab (Ocrevus®): Now also approved in the EU”